Antibody Information

General Information of This Antibody

Antibody ID	ANI0QFTKC
Antibody Name	Serclutamab
Organization	AbbVie, Inc.
Indication	Solid tumors
Synonyms	ABT-806 AM1; ABBV-321; PR1594407; PR-1594407; DC-1630423; ABT-806 affinity-matured AM1 S238C antibody Click to Show/Hide
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Chimeric IgG1-kappa
Antigen Name	Epidermal growth factor receptor (EGFR)	Antigen Info
ChEMBI ID	CHEMBL4594391
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRY QPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPCVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
Heavy Chain Varible Domain	EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRY QPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS Click to Show/Hide
Heavy Chain Constant Domain 1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
Heavy Chain Constant Domain 2	APELLGGPCVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
Heavy Chain Constant Domain 3	GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
Heavy Chain Hinge Region	EPKSCDKTHTCPPCP Click to Show/Hide
Heavy Chain CDR 1	GYSISRDFA Click to Show/Hide
Heavy Chain CDR 2	ISYNGNT Click to Show/Hide
Heavy Chain CDR 3	VTASRGFPY Click to Show/Hide
Light Chain Sequence	DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPS RFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
Light Chain Varible Domain	DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPS RFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK Click to Show/Hide
Light Chain Constant Domain	RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
Light Chain CDR 1	QDINSN Click to Show/Hide
Light Chain CDR 2	HGT Click to Show/Hide
Light Chain CDR 3	VQYAQFPWT Click to Show/Hide

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Serclutamab talirine [Phase 1 (discontinued)]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Eligibility requires ECOG 0-1 patients with progressive EGFR+ tumors (GBM/CRC/HNSCC/NSCLC/others) refractory to prior therapies (≤3 cytotoxic lines), measurable disease, and ≥12-week life expectancy, excluding those with uncontrolled CNS metastases, cardiac dysfunction (NYHA III-IV/EF<40%), active infections (CTCAE≥G3), recent major surgery (21 days), or significant effusions/keratitis. Washout periods apply for prior therapies (21 days for most, 5 half-lives for targeted agents). Click to Show/Hide
Administration Dosage	ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
*Related Clinical Trial*
NCT Number	NCT03234712	Clinical Status	PHASE1
Clinical Description	A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Primary Endpoint	The primary pharmacokinetic endpoints evaluate ABBV-321 exposure (AUCt, AUC), peak concentration (Cmax), time to peak (Tmax), elimination characteristics (beta, t1/2) over 78 days, along with dose-escalation outcomes (MTD, RPTD) during the first 28-day cycle in EGFR-overexpressing solid tumor patients.
Other Endpoint	Secondary efficacy measures assess long-term outcomes (PFS, DOR, DCR, TTP, OS up to 5 years) using RECIST 1.1/RANO criteria, QTcF interval changes through 61 days, and ORR in both solid tumors and glioblastoma populations.
Experiment 2 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Partial Response (PR)	4.17%	High EGFR expression (EGFR+++)
Patients Enrolled	Advanced, histologically confirmed solid tumors associated with EGFR overexpression (centralized testing).
Administration Dosage	Ser-T intravenously once every 4 weeks (Q4W; 5-50 ug/kg) in the dose-escalation phase.
*Related Clinical Trial*
NCT Number	NCT03234712	Clinical Status	Phase 1
Clinical Description	A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR).
Primary Endpoint	One patient was PR (N=1/24, 4.17%), 6 patients was SD (N=6/24,25.00%). Median DOR (CR + PR + SD)=6.40 months (95% CI 3.0not reached). The median PFS=1.8 months (95% CI 1.3-5.8), median OS=7.10 months (95% CI: 4.1-12.3).
Other Endpoint	Ser-T RP2D regimen=25 ug/kg Q4W.
Experiment 3 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Partial Response (PR)	4.20%	High EGFR expression (EGFR+++)
Patients Enrolled	Advanced, histologically confirmed solid tumors associated with EGFR overexpression (centralized testing).
Administration Dosage	Ser-T intravenously once every 4 weeks (Q4W; 5-50 ug/kg) in the dose-escalation phase.
*Related Clinical Trial*
NCT Number	NCT03234712	Clinical Status	Phase 1
Clinical Description	A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR).
Primary Endpoint	Responses included 1 partial response (PR), 6 stable disease (SD), 14 progressive disease (PD); 3 patients were not evaluable for response. Median duration of clinical benefit (complete response + PR + SD) was 6.40 months (95% CI: 3.00-not reached).
Other Endpoint	The median PFS was 1.80 months (95% CI: 1.30-5.80) and the median OS was 7.10 months (95% CI: 4.10-12.30).
Experiment 4 Reporting the Activity Date of This ADC				[3]
*Related Clinical Trial*
NCT Number	NCT03234712	Clinical Status	Phase 1
Clinical Description	A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR).

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 10 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 34%	High EGFR expression (EGFR+++)
Method Description	ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
In Vivo Model	Glioblastoma PDX model (PDX: SNO199)
Experiment 2 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 40%	Low EGFR expression (EGFR+)
Method Description	ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
In Vivo Model	Glioblastoma PDX model (PDX: SNO199)
Experiment 3 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,demonstrated with ABBV-321 dosed at 0.15 mg/kg 2 every seven days 3.
In Vivo Model	EGFR-expressing malignant mesothelioma PDX model (PDX: 1174)
Experiment 4 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.57%	Moderate EGFR expression (EGFR++)
Method Description	ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
In Vivo Model	Glioblastoma PDX model (PDX: SNO207)
Experiment 5 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.20%	Moderate EGFR expression (EGFR++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
In Vivo Model	EGFR-expressing GBM brain cancer PDX model (PDX: SNO199)
Experiment 6 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 91.60%	Moderate EGFR expression (EGFR++)
Method Description	ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
In Vivo Model	Glioblastoma PDX model (PDX: SNO207)
Experiment 7 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.70%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
In Vivo Model	EGFR-expressing GBM brain cancer PDX model (PDX: SNO207)
Experiment 8 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.80%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression, administered at 0.5 mg/kg on a Q7D 6 regimen.
In Vivo Model	EGFR-expressing colorectal adenocarcinoma PDX model (PDX: LoVo)
Experiment 9 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.40%	Moderate EGFR expression (EGFR++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
In Vivo Model	EGFR-expressing GBM brain cancer PDX model (PDX: SNO207)
Experiment 10 Reporting the Activity Date of This ADC				[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.20%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
In Vivo Model	EGFR-expressing GBM brain cancer PDX model (PDX: SNO199)

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 16 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.40%	Moderate EGFR expression (EGFR++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.0125 mg/kg.
In Vivo Model	EGFR-expressing SW48 CDX model
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 2 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 55.30%	Low EGFR expression (EGFR+)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of lung squamous cell carcinoma cell with EGFR expression,a single dose of 0.1 mg/kg.
In Vivo Model	EGFR-expressing EBC-1 CDX model
In Vitro Model	Lung squamous cell carcinoma	EBC-1 cells		CVCL_2891
Experiment 3 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 70.60%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.025 mg/kg.
In Vivo Model	EGFR-expressing SW48 CDX model
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 4 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 73.80%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
In Vivo Model	EGFR-expressing A-253 CDX model
In Vitro Model	Submandibular gland squamous cell carcinoma	A-253 cells		CVCL_1060
Experiment 5 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.10%	Moderate EGFR expression (EGFR++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.3 mg/kg.
In Vivo Model	EGFR-expressing A-253 CDX model
In Vitro Model	Submandibular gland squamous cell carcinoma	A-253 cells		CVCL_1060
Experiment 6 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 82.80%	Moderate EGFR expression (EGFR++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
In Vivo Model	EGFR-expressing SW48 CDX model
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 7 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 82.80%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.05 mg/kg.
In Vivo Model	EGFR-expressing SW48 CDX model
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 8 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.10%	Moderate EGFR expression (EGFR++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
In Vivo Model	EGFR-expressing FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 9 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.90%	Low EGFR expression (EGFR+)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,administered 0.4 mg/kg,at every seven days 3.
In Vivo Model	EGFR-expressing HCT 116 CDX model
In Vitro Model	Colon carcinoma	HCT 116 cells		CVCL_0291
Experiment 10 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.90%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
In Vivo Model	EGFR-expressing HCT 116 CDX model
In Vitro Model	Colon carcinoma	HCT 116 cells		CVCL_0291
Experiment 11 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 91.80%	Negative EGFR expression (EGFR-)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.3 mg/kg.
In Vivo Model	EGFR-expressing FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 12 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High EGFR expression (EGFR+++)
Method Description	ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
In Vivo Model	Glioblastoma U-87MG CDX model
In Vitro Model	Glioblastoma	U-87MG ATCC cells		CVCL_0022
Experiment 13 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low EGFR expression (EGFR+)
Method Description	ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
In Vivo Model	Glioblastoma U-87MG CDX model
In Vitro Model	Glioblastoma	U-87MG ATCC cells		CVCL_0022
Experiment 14 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Low EGFR expression (EGFR+)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of lung squamous cell carcinoma cell with EGFR expression,a single dose of 0.3 mg/kg.
In Vivo Model	EGFR-expressing EBC-1 CDX model
In Vitro Model	Lung squamous cell carcinoma	EBC-1 cells		CVCL_2891
Experiment 15 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
In Vivo Model	EGFR-expressing U-87MG CDX model
In Vitro Model	Glioblastoma	U-87MG ATCC cells		CVCL_0022
Experiment 16 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High EGFR expression (EGFR+++)
Method Description	Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
In Vivo Model	EGFR-expressing U-87MG CDX model
In Vitro Model	Glioblastoma	U-87MG ATCC cells		CVCL_0022

Revealed Based on the Cell Line Data

Click To Hide/Show 38 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15 pM
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 2 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.23 nM	Negative EGFR expression (EGFR-)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Glioblastoma	U-87 MGvIII cells		CVCL_0022
Experiment 3 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.7 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 4 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.7 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Astrocytoma	U-251MG cells		CVCL_0021
Experiment 5 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1 nM	Moderate EGFR expression (EGFR++; IHC 2+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 6 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.1 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	SK-CO-1 cells		CVCL_0626
Experiment 7 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.4 nM	Negative EGFR expression (EGFR-)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Astrocytoma	SF268 cells		CVCL_1689
Experiment 8 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.5 nM	Moderate EGFR expression (EGFR++)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 9 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.5 nM	Low EGFR expression (EGFR+; IHC 1+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Glioblastoma	M059K cells		CVCL_0401
Experiment 10 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.8 nM	Moderate EGFR expression (EGFR++; IHC 2+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	SW403 cells		CVCL_0545
Experiment 11 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.9 nM	High EGFR expression (EGFR+++)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Primitive neuroectodermal tumor	PFSK-1 cells		CVCL_1642
Experiment 12 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.5 nM	High EGFR expression (EGFR+++)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Gliosarcoma	SF539 cells		CVCL_1691
Experiment 13 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.6 nM	Moderate EGFR expression (EGFR++)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	COLO 201 cells		CVCL_1987
Experiment 14 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.8 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Glioblastoma	M059J cells		CVCL_0400
Experiment 15 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.3 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218
Experiment 16 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.7 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Astrocytoma	SNB-19 cells		CVCL_0535
Experiment 17 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.3 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	SW620 cells		CVCL_0547
Experiment 18 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.6 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	SW1116 cells		CVCL_0544
Experiment 19 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.6 nM	Low EGFR expression (EGFR+; IHC 1+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 20 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.7 nM	Low EGFR expression (EGFR+; IHC 1+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon carcinoma	RKO cells		CVCL_0504
Experiment 21 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.8 nM	Moderate EGFR expression (EGFR++)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Rectal adenocarcinoma	SW1463 cells		CVCL_1718
Experiment 22 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.8 nM	Negative EGFR expression (EGFR-)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Anaplastic astrocytoma	CHLA-03-AA cells		CVCL_U616
Experiment 23 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.5 nM	Moderate EGFR expression (EGFR++)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	WiDr cells		CVCL_2760
Experiment 24 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8 nM	Moderate EGFR expression (EGFR++; IHC 2+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 25 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.4 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Glioblastoma	LN-18 cells		CVCL_0392
Experiment 26 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	DLD-1 cells		CVCL_0248
Experiment 27 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.5 nM	Moderate EGFR expression (EGFR++; IHC 2+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Cecum adenocarcinoma	LS1034 cells		CVCL_1382
Experiment 28 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.6 nM	Negative EGFR expression (EGFR-)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Glioblastoma	SNB-75 cells		CVCL_1706
Experiment 29 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.8 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	T84 cells		CVCL_0555
Experiment 30 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon carcinoma	HCT 116 cells		CVCL_0291
Experiment 31 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.9 nM	Low EGFR expression (EGFR+; IHC 1+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	Caco-2 cells		CVCL_0025
Experiment 32 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	14.5 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Glioblastoma	T98G cells		CVCL_0556
Experiment 33 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	16.1 nM	Low EGFR expression (EGFR+; IHC 1+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Astrocytoma	U-138MG cells		CVCL_0020
Experiment 34 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.6 nM	Low EGFR expression (EGFR+; IHC 1+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	COLO 320DM cells		CVCL_0219
Experiment 35 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 36 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23.2 nM
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Glioblastoma	A-172 cells		CVCL_0131
Experiment 37 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24.9 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	COLO 320HSR cells		CVCL_0220
Experiment 38 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.4 nM	High EGFR expression (EGFR+++; IHC 3+)
Method Description	The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
In Vitro Model	Colon adenocarcinoma	HCT 15 cells		CVCL_0292

References

Ref 1	A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Ref 2	Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Neurooncol Adv. 2022 Dec 21;5(1):vdac183.
Ref 3	A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Ref 4	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate. Mol Cancer Ther. 2020 Oct;19(10):2117-2125.

Antibody Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)